QUINCE THERAPEUTICS, INC.

Analyst Reco. Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq Other stock markets 21:30:00 30/04/2024 BST			5-day change	1st Jan Change
1.07 ^USD	+1.42%		-3.60%	+1.90%

04-01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-26	Transcript : Quince Therapeutics, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fed Rate Announcement Eyed as Exchange-Traded Funds, Equity Futures Mixed Premarket Wednesday	22/03/23	MT
HC Wainwright Adjusts Cortexyme's Price Target to $15 From $30, Reiterates Buy Rating	09/03/22	MT
Canaccord Genuity Downgrades Cortexyme to Hold From Buy	28/01/22	MT
JMP Securities Downgrades Cortexyme to Market Perform From Market Outperform	27/01/22	MT
Citigroup Adjusts Cortexyme's Price Target to $2 From $5, Maintains Sell Rating	11/11/21	MT
BofA Securities Cuts Cortexyme to Underperform From Neutral	27/10/21	MT
HC Wainwright Adjusts Cortexyme's Price Target to $30 From $200, Reiterates Buy Rating	27/10/21	MT
Credit Suisse Lowers Cortexyme's PT to $11 from $14 After Alzheimer's Drug Trial Fails to Meet Primary Goals, Keeps Underperform Rating	27/10/21	MT
Canaccord Genuity Adjusts Cortexyme's Price Target to $75 From $150, Reiterates Buy Rating	27/10/21	MT
CORTEXYME : Canaccord Genuity Adjusts Cortexyme's Price Target to $150 from $75, Keeps Buy Rating	16/09/21	MT
CORTEXYME : HC Wainwright Adjusts Cortexyme's Price Target to $200 From $76, Keeps Buy Rating	26/08/21	MT
CORTEXYME : Jefferies Downgrades Cortexyme to Hold From Buy, Adjusts Price Target to $34 From $59	17/02/21	MT
CORTEXYME : Citigroup Starts Cortexyme at Sell With $20 Price Target	11/12/20	MT
CORTEXYME : BofA Securities Upgrades Cortexyme to Buy from Neutral	07/12/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer